Health and wellness company Perrigo Company plc (NYSE; TASE: PRGO) reported on Monday that it has received US Food and Drug Administration tentative approval for the generic version of Finacea Foam(azelaic acid) 15%.
The company added that it had announced a patent litigation suit with Bayer AG for the Finacea Foam (azelaic acid) 15%.
In conjunction with the patent litigation suit, LEO Pharma A/S acquired Finacea Foam (azelaic acid) 15% from Bayer AG and then substituted for Bayer AG as the lead plaintiff in the patent litigation suit concerning the product.
For the 12 months ending January 2019, the annual market sales were approximately USD62m as measured by IQVIA.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical